# Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer

> **NCT03311750** · PHASE2 · TERMINATED · sponsor: **Hellenic Cooperative Oncology Group** · enrollment: 23 (actual)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT03311750
- **Lead sponsor:** Hellenic Cooperative Oncology Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-26
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-05-20
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** It was considered that the recruitment of the remaining 10 patients required of the trial will not be possible soon.
- **Last updated:** 2021-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03311750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03311750, "Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03311750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*